- Business After five years, Verily shelves project to create glucose-sensing contact lens
- First Opinion U.S. hospitals ignore improving elder care. That’s a mistake
- The Readout LOUD LISTEN: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts
- Politics A newcomer rises to the defense of pharma — and tries to salvage its bruised reputation
- Biotech Sick of a daily pill? A Boston biotech wants to make a daily Alzheimer’s drug last for a week — and they’re working on more
- First Opinion Epilepsy, my life-threatening condition, is not your ‘undue burden’
- Health Why fentanyl is deadlier than heroin, in a single photo
- Biotech Offering free DNA sequencing, Nebula Genomics opens for business. But there’s an itsy-bitsy catch
-
- In the Lab How an outsider in Alzheimer’s research bucked the prevailing theory — and clawed for validation
- Business After five years, Verily shelves project to create glucose-sensing contact lens
